Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 9, 2016, Pages 2219-2231

  Rajan, Arun ^a   Kim, Chul ^a   Heery, Christopher R ^a   Guha, Udayan ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

immune checkpoint inhibitors; immunotherapy; melanoma; nivolumab; non small cell lung cancer; renal cell carcinoma

Indexed keywords

AFATINIB; ALPHA2A INTERFERON; AXITINIB; AZACITIDINE; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CERITINIB; CRIZOTINIB; DABRAFENIB; DOCETAXEL; ERLOTINIB; GAMMA INTERFERON; GEFITINIB; IMMUNOGLOBULIN G ANTIBODY; IPILIMUMAB; LIRILUMAB; NIVOLUMAB; PACLITAXEL; PAZOPANIB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SORAFENIB; SUNITINIB; TRAMETINIB; UNINDEXED DRUG; URELUMAB; VARLILUMAB; VEMURAFENIB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHEMORADIOTHERAPY; ELIMINATION HALF-LIFE; FATIGUE; HODGKIN DISEASE; HUMAN; IMMUNIZATION; KIDNEY CARCINOMA; LUNG HEMORRHAGE; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CLINICAL TRIAL (TOPIC); IMMUNOTHERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84987816326     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1175694     Document Type: Review

References (93)

1. B.Krone, K.F.Kolmel, J.M.Grange. The biography of the immune system and the control of cancer:from St Peregrine to contemporary vaccination strategies. BMC Cancer 2014; 14:595; PMID:25128300; http://dx.doi.org/10.1186/1471-2407-14-595
2. C.R.Parish. Cancer immunotherapy:the past, the present and the future. Immunol Cell Biol 2003; 81:106-13; PMID:12631233; http://dx.doi.org/10.1046/j.0818-9641.2003.01151.x
3. M.B.Atkins, M.Sznol. Cancer Immunotherapy:Past Progress and Future Directions. Semin Oncol 2015; 42:518-22; PMID:26320057; http://dx.doi.org/10.1053/j.seminoncol.2015.05.001
4. D.S.Chen, I.Mellman. Oncology meets immunology:the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
5. S.L.Topalian, G.J.Weiner, D.M.Pardoll. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/JCO.2011.38.0899
6. D.Pardoll. Cancer and the Immune System:Basic Concepts and Targets for Intervention. Semin Oncol 2015; 42:523-38; PMID:26320058; http://dx.doi.org/10.1053/j.seminoncol.2015.05.003
7. A.Ribas. Releasing the Brakes on Cancer Immunotherapy. N Engl J Med 2015; 373:1490-2; PMID:26348216; http://dx.doi.org/10.1056/NEJMp1510079
8. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
9. M.S.Barbee, A.Ogunniyi, T.Z.Horvat, T.O.Dang. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015; 49:907-37; PMID:25991832; http://dx.doi.org/10.1177/1060028015586218
10. E.Cha, J.Wallin, M.Kowanetz. PD-L1 inhibition with MPDL3280A for solid tumors. Semin Oncol 2015; 42:484-7; PMID:25965367; http://dx.doi.org/10.1053/j.seminoncol.2015.02.002
11. E.Sharon, H.Streicher, P.Goncalves, H.X.Chen. Immune checkpoint inhibitors in clinical trials. Chin J Cancer 2014; 33:434-44; PMID:25189716; http://dx.doi.org/10.5732/cjc.014.10122
12. FDA product label for nivolmab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s012lbl.pdf
13. G.A.Masters, S.Temin, C.G.Azzoli, G.Giaccone, S.Baker, Jr, J.R.Brahmer, P.M.Ellis, A.Gajra, N.Rackear, J.H.Schiller, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer:American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3488-515; PMID:26324367; http://dx.doi.org/10.1200/JCO.2015.62.1342
14. E.Massarelli, F.Andre, D.D.Liu, J.J.Lee, M.Wolf, A.Fandi, J.Ochs, T.Le Chevalier, F.Fossella, R.S.Herbst. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39:55-61; PMID:12499095; http://dx.doi.org/10.1016/S0169-5002(02)00308-2
15. A.Rajan, D.S.Schrump. Precision Therapy for Lung Cancer:Tyrosine Kinase Inhibitors and Beyond. Semin Thorac Cardiovasc Surg 2015; 27:36-48; PMID:26074108; http://dx.doi.org/10.1053/j.semtcvs.2015.04.002
16. R.Rosell, E.Carcereny, R.Gervais, A.Vergnenegre, B.Massuti, E.Felip, R.Palmero, R.Garcia-Gomez, C.Pallares, J.M.Sanchez, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC):a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-46; PMID:22285168; http://dx.doi.org/10.1016/S1470-2045(11)70393-X
17. M.Maemondo, A.Inoue, K.Kobayashi, S.Sugawara, S.Oizumi, H.Isobe, A.Gemma, M.Harada, H.Yoshizawa, I.Kinoshita, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8; PMID:20573926; http://dx.doi.org/10.1056/NEJMoa0909530
18. L.V.Sequist, J.C.Yang, N.Yamamoto, K.O'Byrne, V.Hirsh, T.Mok, S.L.Geater, S.Orlov, C.M.Tsai, M.Boyer, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327-34; PMID:23816960; http://dx.doi.org/10.1200/JCO.2012.44.2806
19. A.T.Shaw, D.W.Kim, K.Nakagawa, T.Seto, L.Crinó, M.J.Ahn, T.De Pas, B.Besse, B.J.Solomon, F.Blackhall, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-94; PMID:23724913; http://dx.doi.org/10.1056/NEJMoa1214886
20. A.T.Shaw, D.W.Kim, R.Mehra, D.S.Tan, E.Felip, L.Q.Chow, D.R.Camidge, J.Vansteenkiste, S.Sharma, T.De Pas, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370:1189-97; PMID:24670165; http://dx.doi.org/10.1056/NEJMoa1311107
21. M.R.Middleton, J.J.Grob, N.Aaronson, G.Fierlbeck, W.Tilgen, S.Seiter, M.Gore, S.Aamdal, J.Cebon, A.Coates, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-66; PMID:10623706
22. M.B.Atkins, M.T.Lotze, J.P.Dutcher, R.I.Fisher, G.Weiss, K.Margolin, J.Abrams, M.Sznol, D.Parkinson, M.Hawkins, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma:analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16; PMID:10561265
23. H.Davies, G.R.Bignell, C.Cox, P.Stephens, S.Edkins, S.Clegg, J.Teague, H.Woffendin, M.J.Garnett, W.Bottomley, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54; PMID:12068308; http://dx.doi.org/10.1038/nature00766
24. P.B.Chapman, A.Hauschild, C.Robert, J.B.Haanen, P.Ascierto, J.Larkin, R.Dummer, C.Garbe, A.Testori, M.Maio, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
25. A.Hauschild, J.J.Grob, L.V.Demidov, T.Jouary, R.Gutzmer, M.Millward, P.Rutkowski, C.U.Blank, W.H.Miller, Jr, E.Kaempgen, et al. Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-65; PMID:22735384; http://dx.doi.org/10.1016/S0140-6736(12)60868-X
26. K.T.Flaherty, C.Robert, P.Hersey, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367:107-14; PMID:22663011; http://dx.doi.org/10.1056/NEJMoa1203421
27. C.Robert, B.Karaszewska, J.Schachter, P.Rutkowski, A.Mackiewicz, D.Stroiakovski, M.Lichinitser, R.Dummer, F.Grange, L.Mortier, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
28. G.V.Long, D.Stroyakovskiy, H.Gogas, E.Levchenko, F.de Braud, J.Larkin, C.Garbe, T.Jouary, A.Hauschild, J.J.Grob, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371:1877-88; PMID:25265492; http://dx.doi.org/10.1056/NEJMoa1406037
29. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
30. D.Schadendorf, F.S.Hodi, C.Robert, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
31. FDA product label for ipilimumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s074lbl.pdf
32. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.J.Hwu, T.C.Gangadhar, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma:a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
33. FDA product label for pembrolizumab. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf
34. D.F.McDermott, M.M.Regan, J.I.Clark, L.E.Flaherty, G.R.Weiss, T.F.Logan, J.M.Kirkwood, M.S.Gordon, J.A.Sosman, M.S.Ernstoff, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-41; PMID:15625368; http://dx.doi.org/10.1200/JCO.2005.03.206
35. B.Escudier, T.Eisen, W.M.Stadler, C.Szczylik, S.Oudard, M.Staehler, S.Negrier, C.Chevreau, A.A.Desai, F.Rolland, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34; PMID:17215530; http://dx.doi.org/10.1056/NEJMoa060655
36. R.J.Motzer, T.E.Hutson, P.Tomczak, M.D.Michaelson, R.M.Bukowski, O.Rixe, S.Oudard, S.Negrier, C.Szczylik, S.T.Kim, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-24; PMID:17215529; http://dx.doi.org/10.1056/NEJMoa065044
37. C.N.Sternberg, I.D.Davis, J.Mardiak, C.Szczylik, E.Lee, J.Wagstaff, C.H.Barrios, P.Salman, O.A.Gladkov, A.Kavina, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma:results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-8; PMID:20100962; http://dx.doi.org/10.1200/JCO.2009.23.9764
38. B.I.Rini, B.Escudier, P.Tomczak, A.Kaprin, C.Szczylik, T.E.Hutson, M.D.Michaelson, V.A.Gorbunova, M.E.Gore, I.G.Rusakov, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomised phase 3 trial. Lancet 2011; 378:1931-9; PMID:22056247; http://dx.doi.org/10.1016/S0140-6736(11)61613-9
39. G.Hudes, M.Carducci, P.Tomczak, J.Dutcher, R.Figlin, A.Kapoor, E.Staroslawska, J.Sosman, D.McDermott, I.Bodrogi, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81; PMID:17538086; http://dx.doi.org/10.1056/NEJMoa066838
40. R.J.Motzer, B.Escudier, S.Oudard, T.E.Hutson, C.Porta, S.Bracarda, V.Grünwald, J.A.Thompson, R.A.Figlin, N.Hollaender, et al. Efficacy of everolimus in advanced renal cell carcinoma:a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-56; PMID:18653228; http://dx.doi.org/10.1016/S0140-6736(08)61039-9
41. B.Escudier, A.Pluzanska, P.I.Koralewski. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma:a randomised, double-blind phase III trial. Lancet 2007; 370:2103-11; PMID:18156031; http://dx.doi.org/10.1016/S0140-6736(07)61904-7
42. L.Albiges, T.Choueiri, B.Escudier, M.Galsky, D.George, F.Hofmann, T.Lam, R.Motzer, P.Mulders, C.Porta, et al. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 2015; 67:100-10; PMID:24841777; http://dx.doi.org/10.1016/j.eururo.2014.04.006
43. T.Okazaki, S.Chikuma, Y.Iwai, S.Fagarasan, T.Honjo. A rheostat for immune responses:the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013; 14:1212-8; PMID:24240160; http://dx.doi.org/10.1038/ni.2762
44. R.J.Greenwald, G.J.Freeman, A.H.Sharpe. The B7 family revisited. Annu Rev Immunol 2005; 23:515-48; PMID:15771580; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115611
45. H.Dong, S.E.Strome, D.R.Salomao, H.Tamura, F.Hirano, D.B.Flies, P.C.Roche, J.Lu, G.Zhu, K.Tamada, et al. Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nat Med 2002; 8:793-800; PMID:12091876; http://dx.doi.org/10.1038/nm0902-1039c
46. X.Meng, Z.Huang, F.Teng, L.Xing, J.Yu. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 2015; 41:868-76; PMID:26589760; http://dx.doi.org/10.1016/j.ctrv.2015.11.001
47. P.Sharma, J.P.Allison. The future of immune checkpoint therapy. Science 2015; 348:56-61; PMID:25838373; http://dx.doi.org/10.1126/science.aaa8172
48. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, J.Weber, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
49. G.J.Freeman, A.J.Long, Y.Iwai, K.Bourque, T.Chernova, H.Nishimura, L.J.Fitz, N.Malenkovich, T.Okazaki, M.C.Byrne, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
50. J.R.Brahmer, H.Hammers, E.J.Lipson. Nivolumab:targeting PD-1 to bolster antitumor immunity. Future Oncol 2015; 11:1307-26; PMID:25798726; http://dx.doi.org/10.2217/fon.15.52
51. C.Wang, K.B.Thudium, M.Han, X.T.Wang, H.Huang, D.Feingersh, C.Garcia, Y.Wu, M.Kuhne, M.Srinivasan, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2:846-56; PMID:24872026; http://dx.doi.org/10.1158/2326-6066.CIR-14-0040
52. J.R.Brahmer, C.G.Drake, I.Wollner, J.D.Powderly, J.Picus, W.H.Sharfman, E.Stankevich, A.Pons, T.M.Salay, T.L.McMiller, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; http://dx.doi.org/10.1200/JCO.2009.26.7609
53. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
54. Y.Feng, G.Bajaj, X.Wang, et al. Model-based analysis of nivolumab to support clinical pharmacology profiling in subjects with solid tumors. Clin Pharmacol Ther 2015; 97(Suppl 1):S41-2
55. C.Passey, J.Simon, Q.Hong, et al. Assessment of drug interaction potential by nivolumab using cytokine modulation data. Clin Pharmacol Ther 2015; 97(Suppl 1):S96.
56. S.Agrawal, D.Williams, I.Waxman, et al. Absence of QT prolongation (QTP) effect by nivolumab (nivo) or ipilimumab (ipi) in subjects with solid tumors. Clin Pharmacol Ther 2015; 97(Suppl 1):S95-6
57. J.Brahmer, K.L.Reckamp, P.Baas, L.Crin∫, W.E.Eberhardt, E.Poddubskaya, S.Antonia, A.Pluzanski, E.E.Vokes, E.Holgado, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
58. H.Borghaei, L.Paz-Ares, L.Horn, D.R.Spigel, M.Steins, N.E.Ready, L.Q.Chow, E.E.Vokes, E.Felip, E.Holgado, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
59. S.N.Gettinger, F.A.Shepherd, S.J.Antonia, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC:Safety, efficacy, and correlation of outcomes with PD-L1 status. ASCO Meeting Abstracts 2014; 32:8024
60. S.J.Antonia, J.R.Brahmer, S.N.Gettinger, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32:8113
61. S.J.Antonia, S.N.Gettinger, L.Q.M.Chow, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC:Interim phase I results. ASCO Meeting Abstracts 2014; 32:8023
62. N.A.Rizvi, L.Q.M.Chow, H.Borghaei, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meeting Abstracts 2014; 32:8022
63. J.S.Weber, S.P.D'Angelo, D.Minor, F.S.Hodi, R.Gutzmer, B.Neyns, C.Hoeller, N.I.Khushalani, W.H.Miller, Jr, C.D.Lao, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
64. C.Robert, G.V.Long, B.Brady, C.Dutriaux, M.Maio, L.Mortier, J.C.Hassel, P.Rutkowski, C.McNeil, E.Kalinka-Warzocha, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
65. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
66. M.A.Postow, J.Chesney, A.C.Pavlick, C.Robert, K.Grossmann, D.McDermott, G.P.Linette, N.Meyer, J.K.Giguere, S.S.Agarwala, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-17; PMID:25891304; http://dx.doi.org/10.1056/NEJMoa1414428
67. R.J.Motzer, B.I.Rini, D.F.McDermott, B.G.Redman, T.M.Kuzel, M.R.Harrison, U.N.Vaishampayan, H.A.Drabkin, S.George, T.F.Logan, et al. Nivolumab for Metastatic Renal Cell Carcinoma:Results of a Randomized Phase II Trial. J Clin Oncol 2015; 33:1430-7; PMID:25452452; http://dx.doi.org/10.1200/JCO.2014.59.0703
68. R.J.Motzer, B.Escudier, D.F.McDermott, S.George, H.J.Hammers, S.Srinivas, S.S.Tykodi, J.A.Sosman, G.Procopio, E.R.Plimack, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
69. H.J.Hammers, E.R.Plimack, J.R.Infante, et al. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2014; 32:4504
70. H.J.Hammers, E.R.Plimack, J.R.Infante, et al. Expanded cohort results from CheckMate 016:A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2015; 33:4516
71. A.Amin, E.R.Plimack, J.R.Infante, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts 2014; 32:5010
72. S.J.Antonia, J.C.Bendell, M.H.Taylor, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC):CA209-032. ASCO Meeting Abstracts 2015; 33:7503
73. D.Le, J.Bendell, E.Calvo, et al. Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC):Results from the CheckMate-032 study. J Clin Oncol 2016; 34:6; PMID:26578608; http://dx.doi.org/10.1200/JCO.2015.62.2860
74. S.M.Ansell, A.M.Lesokhin, I.Borrello, A.Halwani, E.C.Scott, M.Gutierrez, S.J.Schuster, M.M.Millenson, D.Cattry, G.J.Freeman, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
75. J.Hamanishi, M.Mandai, T.Ikeda, M.Minami, A.Kawaguchi, T.Murayama, M.Kanai, Y.Mori, S.Matsumoto, S.Chikuma, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol 2015; 33:4015-22; PMID:26351349; http://dx.doi.org/10.1200/JCO.2015.62.3397
76. T.Kojima, H.Hara, K.Yamaguchi, et al. Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer:Preliminary report of overall survival. J Clin Oncol 2016; 34:TPS175
77. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
78. L.Carbognin, S.Pilotto, M.Milella, V.Vaccaro, M.Brunelli, A.Cali∫, F.Cuppone, I.Sperduti, D.Giannarelli, M.Chilosi, et al. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1):Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One 2015; 10:e0130142; PMID:26086854; http://dx.doi.org/10.1371/journal.pone.0130142
79. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
80. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.1158/1078-0432.CCR-13-3271
81. D.T.Le, J.N.Uram, H.Wang, B.R.Bartlett, H.Kemberling, A.D.Eyring, A.D.Skora, B.S.Luber, N.S.Azad, D.Laheru, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596
82. I.Melero, D.M.Berman, M.A.Aznar, A.J.Korman, J.L.Pérez Gracia, J.Haanen. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15:457-72; PMID:26205340; http://dx.doi.org/10.1038/nrc3973
83. M.B.Atkins, J.Larkin. Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors:Current Perspectives. J Natl Cancer Inst 2016; 108:djv414; PMID:26839346
84. S.R.Woo, M.E.Turnis, M.V.Goldberg, J.Bankoti, M.Selby, C.J.Nirschl, M.L.Bettini, D.M.Gravano, P.Vogel, C.L.Liu, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
85. J.Fourcade, Z.Sun, M.Benallaoua, P.Guillaume, I.F.Luescher, C.Sander, J.M.Kirkwood, V.Kuchroo, H.M.Zarour. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
86. K.Sakuishi, L.Apetoh, J.M.Sullivan, B.R.Blazar, V.K.Kuchroo, A.C.Anderson. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
87. S.Aspeslagh, S.Postel-Vinay, S.Rusakiewicz, J.C.Soria, L.Zitvogel, A.Marabelle. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer 2016; 52:50-66; PMID:26645943; http://dx.doi.org/10.1016/j.ejca.2015.08.021
88. A.Yonezawa, S.Dutt, C.Chester, J.Kim, H.E.Kohrt. Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. Clin Cancer Res 2015; 21:3113-20; PMID:25908780; http://dx.doi.org/10.1158/1078-0432.CCR-15-0263
89. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
90. S.C.Formenti, S.Demaria. Combining radiotherapy and cancer immunotherapy:a paradigm shift. J Natl Cancer Inst 2013; 105:256-65; PMID:23291374; http://dx.doi.org/10.1093/jnci/djs629
91. T.F.Gajewski. The Next Hurdle in Cancer Immunotherapy:Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol 2015; 42:663-71; PMID:26320069; http://dx.doi.org/10.1053/j.seminoncol.2015.05.011
92. T.F.Gajewski, S.R.Woo, Y.Zha, R.Spaapen, Y.Zheng, L.Corrales, S.Spranger. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013; 25:268-76; PMID:23579075; http://dx.doi.org/10.1016/j.coi.2013.02.009
93. J.Larkin, F.S.Hodi, J.D.Wolchok. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:1270-1; PMID:26398076; http://dx.doi.org/10.1056/NEJMoa1504030